Subscribe X
Back to Top

Learn

Archives

January 16, 2015 by Bob Nikkel, MSW

New CEU/CME Course Available: Psychiatric Medications and Long-term Outcomes for Schizophrenia

bnikkel_miaceThe Mad in America Continuing Education Project is pleased to announce the posting of its second on-line course.

This course qualifies for 3.0 CMEs  approved by the American Academy of Family Physicians and 2.5 CEUs approved by Commonwealth Educational Seminars for psychologists, social workers, licensed marriage and family counselors, nurses and certified addiction counselors.

We are fortunate to have enlisted the expertise of one of the world’s premier researchers, Martin Harrow, PhD, of the University of Illinois Chicago Medical School as he presents his 26-year comprehensive outcome study of individuals diagnosed with schizophrenia and other psychotic disorders.

The course includes a one-hour discussion moderated by Bob Whitaker which includes Dr. Harrow’s chief collaborator, Dr. Thomas Jobe. The two lessons together focus on the improved outcomes for people who stopped taking antipsychotic medications compared to those on antipsychotics.

Instructor

Martin-HarrowMartin Harrow, PhD

Martin Harrow is a psychologist and widely-cited expert on schizophrenia and bipolar disorders. He has published over 250 scientific papers and four books on these and related areas. As Director of the Chicago Followup Study, he has received several national awards for his research on thought disorder, psychosis, long-term adjustment, suicide, and recovery in schizophrenia. Recently his research has focused on longitudinal studies of the long-term effects of antipsychotic medications. He has been on the faculty at Yale University and the University of Chicago, and in 1990, moved to the Medical College of the University of Illinois as Professor and Director of Psychology in the Department of Psychiatry. He is now Distinguished Professor Emeritus there.

We look forward to sharing the work Dr. Harrow, Dr. Jobe and other colleagues in better understanding the relationship between long-term use or non-use of psychiatric medications and important outcomes like functional status, psychotic symptoms and rehospitalization.

Read More

September 7, 2013 by Hikaru Hori et al

Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients

elsevierHikaru Hori, Reiji YoshimuraAsuka KatsukiAtsuko-Ikenouchi SugitaKiyokazu AtakeJun Nakamura

Department of Psychiatry, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka 8078555, Japan

Abstract

Objective

This study sought to examine whether switching polypharmacy therapy to monotherapy would improve the cognitive function and social function of patients with schizophrenia.

Read More

August 28, 2013 by Thomas Insel, MD

NIMH Director’s Blog: Antipsychotics: Taking the Long View

One of the first lessons I received as a psychiatrist-in-training 35 years ago was the value of antipsychotic medications. These medicines have been available for the treatment of psychosis for over half a century, beginning with the prototype first generation drug chlorpromazine (Thorazine) and now extending to some 20 different compounds, including several second-generation medications, often called “atypical antipsychotics.” Symptoms such as hallucinations, delusions, and paranoia are reduced reliably by these drugs. Although these symptoms can be frightening and dangerous for patients, family members, and providers, antipsychotics safely and effectively help people through the crisis of acute psychosis.

However, the long-term management of chronic mental illness is another matter. Recently, results from several studies have suggested that these medications may be less effective for the outcomes that matter most to people with serious mental illness: a full return to well-being and a productive place in society.

Read More

April 22, 2013 by Sandra Steingard, MD

All Sorts of Realities

In previous posts in this series, I noted that the standard treatment of conditions labeled as schizophrenia (and related disorders) is to start neuroleptics early and to continue them indefinitely. This is based on the belief that untreated psychosis is bad for the brain and that relapse is much higher when the drugs are stopped than when they are continued. The rationale for this approach, and my discussion of the limitations of these assertions, were the topics of previous blogs in this series.

Read More

December 17, 2012 by Courtenay Harding, PhD

“Recovery” Is Not Just a Fad

Courtenay-HardingI want to talk briefly about “recovery.” Many clinicians and program directors were trained, as I was, to think that regaining marginal improvement or downward course were the only two options open for persons with repeated episodes of serious and persistent psychiatric problems, such as the group of schizophrenias, major depressions, or bipolar disorders. However, there have been over 30 follow-up studies, both short and very long, as well as hundreds of former recipients of services all displaying carefully collected data and brilliant examples about the possibilities of significant improvement and even full recovery.

Read More


Related Blogs

  • Dr. David Healy

    Dr. David Healy

    Dr. Healy is a professor of psychiatry at Cardiff University in Wales and an author on the history of pharmaceuticals and government regulation.
    READ BLOG
  • Mad In America: Robert Whitaker

    Mad In America: Robert Whitaker

    Journalist and author Bob Whitaker distills the latest in pharmaceutical and mental health research.
    READ BLOG
  • Selling Sickness

    Selling Sickness

    Creating a new partnership movement to challenge the selling of sickness.
    READ BLOG
  • Kathy Brous

    Kathy Brous

    A serial of Kathy's recovery journey as an adult with attachment disorder.
    READ BLOG
  • Nev Jones

    Nev Jones

    Exploring the intersections of psychiatry, philosophy, neuroscience, cultural theory, critical community psychology and the mad/user/survivor movement.
    READ BLOG
  • 1boringoldman

    1boringoldman

    Retired psychiatrist and raconteur offers insightful analysis of the day's events from the woods of Georgia.
    READ BLOG